BioStem Technologies Strengthens Board of Directors with Key Appointments
BioStem Technologies (OTC: BSEM) has strengthened its Board of Directors this week with the appointment of industry veterans, Mr. Thomas Dugan as Chairman and Mr. Patrick Daly as Executive Director.
BioStem Technologies CEO, Jason Matuszewski, commented, “We are excited to welcome Thomas Dugan and Patrick Daly to BioStem’s Board of Directors and look forward to leveraging their deep industry experience and relationships and benefiting from their leadership as we strategically position BioStem in multiple expanding markets to shape the future of regenerative medicine.”
Highlights
Mr. Dugan brings a wealth of experience to BioStem as a senior executive who has transformed businesses and established new market opportunities, and has extensive experience in the wound care and surgical fields. He co-founded 360 Life Sciences Advisors, a consultancy to private equity and venture capital firms, to assess new investment opportunities and improve performance at portfolio companies. Most recently, Mr. Dugan was the President of Integrum, Inc., the pioneer in osseointegrated orthopedic implants that improve the lives of those with limb loss. Previously, he served as Chief Executive Officer and board member at Amniox Medical, a pioneer in amniotic membrane products for wound care and surgical applications.
Mr. Daly is an award-winning executive leader with a strong track record of success in operations, strategy, sales, marketing, fundraising, and partnership-building. He is an Advisor at Pappas Capital, a private equity firm focused on the life sciences industry. Most recently, he served as Global VP Commercial Solutions and subsequently, Global VP MedTech Data Delivery, at IQVIA Holdings and was responsible for leading a global strategic MedTech Commercial Solutions business unit. Previously, he held the position of President and CEO at Cohera Medical, where he spearheaded the development of a novel delivery device for synthetic surgical adhesive that received the Businesswire 2012 Medical Design Excellence Award.
About BioStem Technologies, Inc.
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (AATB). These systems and procedures are established per current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC® and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA-registered and AATB-accredited site in Pompano Beach, Florida. For more information, visit biostemtechnologies.com and follow us on Twitter and LinkedIn.
Disclaimer
This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…